DAPAGLIFLOZIN: AN ANTI-DIABETIC DRUG WITH CARDIOVASCULAR BENEFITS
AbstractType 2 diabetes mellitus (T2DM) is a chronic disease, and most patients ultimately require two or more anti-hyperglycemic drugs along with lifestyle changes to achieve and maintain glycaemic control. Sodium-glucose co-transporter 2(SGLT2) inhibitors, such as Dapagliflozin, are the newest class of antidiabetic drugs approved for the treatment of T2DM. Dapagliflozin is a highly selective SGLT2 inhibitor that decreases glucose reabsorption by kidneys and thus lowers blood glucose by increasing glucose excretion in urine output. Dapagliflozin effectively improves glycaemic control by increasing the renal excretion of excess glucose. In clinical trials, dapagliflozin has been well-tolerated and safe to be administered to the major population. It has additional benefits of weight loss, low risk of hypoglycemia, reduction in blood pressure, and cardiovascular benefits. Dapagliflozin can be administered as monotherapy on in combination with other antidiabetic drugs. Thus, Dapagliflozin offers a novel treatment option for type 2 diabetes mellitus with additional benefits.
Article Information
3
1986-1993
458
1418
English
IJPSR
S. Kalyan * and A. Parle
Department of Quality Assurance, Delhi Institute of Pharmaceutical Sciences and Research, New Delhi, Delhi, India.
sahil111kalyan@gmail.com
26 July 2019
10 April 2020
11 April 2020
10.13040/IJPSR.0975-8232.11(5).1986-93
01 May 2020
Download